STORY: "Studies have shown that when you go off these drugs, you tend to put the weight right back on," Coons said. "So this ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...

Yet at the annual meeting of the Menopause Society earlier this fall, researchers presented new evidence that hormone therapy ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

Find insight on IHH Healthcare, Novo Nordisk and more in the latest Market Talks covering the Health Care sector.

Novo Nordisk is working to accelerate the launch of its weight-loss drug Wegovy in India, concerned about lagging behind Eli ...

Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

Recent data from an Amgen obesity-drug trial only reinforced investors' impressions that Eli Lilly and Novo Nordisk have a prohibitive head start, thanks, in particular, to a new generation of Lilly ...

The price of Wegovy, the diabetes control drug's glamorous anti-obesity sibling, may also be falling, according to a Health ...